- Home
- CSTL vs LIND Comparison
CSTL vs LIND Comparison
Compare CSTL & LIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- LIND
- Stock Information
- Founded
- CSTL 2007
- LIND 1979
- Country
- CSTL United States
- LIND United States
- Employees
- CSTL N/A
- LIND N/A
- Industry
- CSTL Medical Specialities
- LIND Transportation Services
- Sector
- CSTL Health Care
- LIND Consumer Discretionary
- Exchange
- CSTL Nasdaq
- LIND Nasdaq
- Market Cap
- CSTL 555.8M
- LIND 618.2M
- IPO Year
- CSTL 2019
- LIND N/A
- Fundamental
- Price
- CSTL $24.21
- LIND $14.33
- Analyst Decision
- CSTL Strong Buy
- LIND Strong Buy
- Analyst Count
- CSTL 6
- LIND 3
- Target Price
- CSTL $37.67
- LIND $16.67
- AVG Volume (30 Days)
- CSTL 712.7K
- LIND 442.1K
- Earning Date
- CSTL 08-04-2025
- LIND 08-04-2025
- Dividend Yield
- CSTL N/A
- LIND N/A
- EPS Growth
- CSTL N/A
- LIND N/A
- EPS
- CSTL N/A
- LIND N/A
- Revenue
- CSTL $346,269,000.00
- LIND $702,280,000.00
- Revenue This Year
- CSTL N/A
- LIND $17.93
- Revenue Next Year
- CSTL N/A
- LIND $9.44
- P/E Ratio
- CSTL N/A
- LIND N/A
- Revenue Growth
- CSTL 20.40
- LIND 18.74
- 52 Week Low
- CSTL $14.59
- LIND $7.45
- 52 Week High
- CSTL $35.84
- LIND $15.06
- Technical
- Relative Strength Index (RSI)
- CSTL 76.51
- LIND 58.78
- Support Level
- CSTL $20.35
- LIND $13.50
- Resistance Level
- CSTL $20.80
- LIND $15.04
- Average True Range (ATR)
- CSTL 0.95
- LIND 0.51
- MACD
- CSTL 0.45
- LIND 0.03
- Stochastic Oscillator
- CSTL 96.67
- LIND 64.22
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About LIND Lindblad Expeditions Holdings Inc.
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.